Stock comparison
Halozyme Therapeutics
Vir Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
VIR
Vir Biotechnology
Market cap
$1.52B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | VIR | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 20F | HALO |
| Benjamin Graham | 83A | 37D | HALO |
| Philip Fisher | 65B | 31F | HALO |
| Peter Lynch | 53D | 3F | HALO |
| Joel Greenblatt | 40D | 2F | HALO |
| Charlie Munger | 80C | 38D | HALO |
| Terry Smith | 84A | 38D | HALO |
Side-by-side metrics
| Metric | HALO | VIR |
|---|---|---|
| Market cap | $8.1B | $1.52B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | - |
| ROIC (TTM) | 23.65% | -48.49% |
| Gross margin | 81.24% | 2.75% |
| Net margin | 23.13% | -6.76% |
| Revenue CAGR 5y | 33.23% | -49.98% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -49.98%+166%
- ROIC (TTM)23.65%vs -48.49%+149%
- Net margin23.13%vs -6.76%+103%
- Market cap$8.1Bvs $1.52B+81%
VIR leads on
- EV/EBIT-vs 10.2x+127%
- P/E (TTM)-vs 24.0x+112%
- Debt / Equity0.1xvs 1.0x+89%
- Gross margin2.75%vs 81.24%+70%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.